Oxler Private Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

Oxler Private Wealth’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,480	Closed	-$1.73M	–	237
2022 Q1	$1.73M	Hold	2,480	–	–	0.78%	37
2021 Q4	$1.57M	Hold	2,480	–	–	0.65%	47
2021 Q3	$1.5M	Hold	2,480	–	–	0.66%	45
2021 Q2	$1.39M	Buy	2,480 +200	+9%	+$101K	0.6%	47
2021 Q1	$1.08M	Buy	2,280 +570	+33%	+$278K	0.55%	51
2020 Q4	$652K	Buy	+1,710	New	+$923K	0.37%	63

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Oxler Private Wealth's REGN Position: Q2 2022 in Review

Oxler Private Wealth sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 2,480 shares — an estimated $1.73M sold.

Oxler Private Wealth first reported a position in REGN in Q4 2020 and held it in 6 quarters. The position peaked at $1.73M in Q1 2022. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

Oxler Private Wealth reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Oxler Private Wealth sold 2,480 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $1.73M.
Oxler Private Wealth first reported a position in Regeneron Pharmaceuticals in Q4 2020 and held it in 6 quarters.
Oxler Private Wealth's Regeneron Pharmaceuticals position peaked at $1.73M in Q1 2022.
1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Oxler Private Wealth's 13F filing for Q2 2022, filed 15 Aug 2022.